Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography

Synapse

Volumn 60, Issue 4, 2006, Pages 314-318

  Vasdev, Neil ^a,b   Natesan, Sridhar ^a   Galineau, Laurent ^a   Garcia, Armando ^a   Stableford, Winston T ^a   McCormick, Patrick ^c   Seeman, Philip ^b,c   Houle, Sylvain ^a,b   Wilson, Alan A ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

3 PPP; Carbon 11; D2; Partial agonist; PET; Preclamol; Propylation

Indexed keywords

3 (3 HYDROXYPHENYL)PIPERIDINE; CARBON 11; CARBON DIOXIDE; CHLORIDE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LITHIUM DERIVATIVE; PIPERIDINE DERIVATIVE; PRECLAMOL; PRECLAMOL C 11; PROPIONYL CHLORIDE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BLOOD BRAIN BARRIER; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PURIFICATION; DRUG SYNTHESIS; DRUG UPTAKE; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MICROANALYSIS; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; RAT; REDUCTION; RODENT; SCHIZOPHRENIA;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; CHEMISTRY, PHYSICAL; DOPAMINE AGONISTS; INDICATORS AND REAGENTS; INJECTIONS, INTRAVENOUS; ISOTOPE LABELING; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 33746501398     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20304     Document Type: Article

References (28)

1. 125I]iodosulpride. Neuroscience 20:117-155.
2. Burger C, Buck A. 1997. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 38:1818-1823.
3. De Lean A, Kilpatrick BF, Caron MG. 1982. Guanine nucleotides regulate both dopaminergic agonist and antagonist binding in porcine anterior pituitary. Endocrinology 110:1064-1066.
4. 11C]-(+)-PHNO in rats using an intracerebral β-sensitive system. Synapse 60:172-183.
5. 2 receptors in brain and anterior pituitary recognize agonist and antagonist actions of (-)-3-PPP. J Neural Transm 64:13-33.
6. 11C]raclopride in rats. Synapse 52:89-99.
7. Gjedde A, Wong DF, Rosa-Neto P, Cumming P. 2005. Mapping neuroreceptors at work: On the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol 63:1-20.
8. Hacksell U, Arvidsson LE, Svensson U, Nilsson JLG, Sanchez D, Wikström H, Lindberg P, Hjorth S, Carlsson A. 1981. 3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity. J Med Chem 24:1475-1482.
9. Hume SP, Gunn RN, Jones T. 1998. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 25:173-176.
10. Kenakin TP. 1985. The quantification of relative efficacy of agonists. J Pharmacol Methods 13:281-308.
11. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. 1998. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 43:2-11.
12. Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL. 1992. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities. Mol Pharmacol 42:432-438.
13. 3H]3-(3-hydroxyphenyl)-N- (1-propyl)piperidine. Proc Natl Acad Sci USA 81:4983-4987.
14. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20:423-451.
15. Luthra SK, Pike VW, Brady F. 1990. Preparation of some NCA l-[uC]acid chlorides as labelling agents. Int J Rad Appl Instrum [A] 41:471-476.
16. Pain F, Laniece P, Mastrippolito R, Charon Y, Comar D, Leviel V, Pujol JF, Valentin L. 2000. SIC, an intracerebral radiosensitive probe for in vivo neuropharmacology investigations in small laboratory animals: Theoretical considerations and physical characteristics. IEEE Trans Nucl Sci 47:25-32.
17. Pliska V. 1999. Partial agonism: Mechanisms based on ligand-receptor interactions and on stimulus-response coupling. J Recept Signal Transduct Res 19:597-629.
18. 2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol 28:391-399.
19. 3H] spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 49:209-215.
20. Sibley DR, De Lean A, Creese I. 1982. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D2 dopamine receptor. J Biol Chem 257:6351-6361.
21. Strange PG. 1999. G-protein coupled receptors: Conformations and states. Biochem Pharmacol 58:1081-1088.
22. Tamminga CA. 2002. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411-420.
23. Thorberg SO, Gawell L, Csöregh I, Nilsson JLG. 1985. Large scale synthesis and absolute configuration of (-)-3-PPP, a selective dopamine autoreceptor agonist. Tetrahedron 41:129-139.
24. Waterhouse RN. 2003. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5:376-389.
25. Wikström H, Sanchez D, Lindberg P, Hackseil U, Arvidsson LE, Johansson AM, Thorberg SO, Nilsson JLG, Svensson K, Hjorth S, Clark D, Carlsson A. 1984. Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: Central dopamine receptor activity J Med Chem 27:1030-1036.
26. 18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. Nucl Med Biol 23:141-146.
27. Wilson AA, Jin L, Garcia A, DaSilva JN, Houle S. 2001. An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl Radiat Isot 54:203-208.
28. 11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4] oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153-4160.